Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Building expectations

<< Previous

Bullboard Posts

Next >>

Comment by juniper88on May 12, 2021 9:18pm

148 Views

Post# 33189054

RE:RE:RE:RE:RE:RE:RE:RE:Building expectations

Especially if we don't actually vote anyone off. I voted my almost 200k shares "No" against Mr. Littlejohn. I hope enough others did so at least a statement is made. Things have to change.

jeffm34 wrote:
If anyone here thinks things are going to change just because we talked about voting out a board member or two, you are sadly mistaken.

scarlet1967 wrote: This is from current website, how difficult is it to update the freaking pipeline in timely manner?

Theratechnologies intends to submit its Phase 3 study protocol to the United States Food and Drug Administration (FDA) and the European regulatory agencies in the fourth quarter of 2020. Subject to approval from the regulatory agencies, the enrollment of patients is planned for the first quarter of 2021.